Loading...
•
Mar 31, 2022
ResMed Q3 2022 Earnings Report
ResMed's Q3 2022 results reflected strong performance with double-digit top-line revenue growth and solid high-single-digit growth in software-as-a-service.
Key Takeaways
ResMed Inc. reported a 12% increase in revenue to $864.5 million for the quarter ended March 31, 2022. Diluted earnings per share were $1.22, and non-GAAP diluted earnings per share were $1.32.
Revenue increased by 12% to $864.5 million, or 14% on a constant currency basis.
Gross margin contracted 140 bps to 56.8%, while non-GAAP gross margin contracted 150 bps to 58.1%.
Income from operations increased 5%, with non-GAAP operating profit also up 5%.
Diluted earnings per share were $1.22, and non-GAAP diluted earnings per share were $1.32.
ResMed
ResMed
ResMed Revenue by Geographic Location
Revenue by Geographic Location
U.S., Canada, and Latin America Revenue
CapyFin.comEurope, Asia, and other markets Revenue
CapyFin.com Forward Guidance
The company did not provide specific forward guidance in this earnings report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income